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Abstract
Background: In traditional medicine whole plants or mixtures of plants are used rather than isolated compounds.
There is evidence that crude plant extracts often have greater in vitro or/and in vivo antiplasmodial activity than
isolated constituents at an equivalent dose. The aim of this paper is to review positive interactions between
components of whole plant extracts, which may explain this.
Methods: Narrative review.
Results: There is evidence for several different types of positive interactions between different components of
medicinal plants used in the treatment of malaria. Pharmacodynamic synergy has been demonstrated between the
Cinchona alkaloids and between various plant extracts traditionally combined. Pharmacokinetic interactions occur,
for example between constituents of Artemisia annua tea so that its artemisinin is more rapidly absorbed than the
pure drug. Some plant extracts may have an immunomodulatory effect as well as a direct antiplasmodial effect.
Several extracts contain multidrug resistance inhibitors, although none of these has been tested clinically in
malaria. Some plant constituents are added mainly to attenuate the side-effects of others, for example ginger to
prevent nausea.
Conclusions: More clinical research is needed on all types of interaction between plant constituents. This could
include clinical trials of combinations of pure compounds (such as artemisinin + curcumin + piperine) and of
combinations of herbal remedies (such as Artemisia annua leaves + Curcuma longa root + Piper nigum seeds). The
former may enhance the activity of existing pharmaceutical preparations, and the latter may improve the
effectiveness of existing herbal remedies for use in remote areas where modern drugs are unavailable.
Background
Over 1,277 plants belonging to 160 families were
reported in 2004 to be used traditionally for the treat-
ment of malaria following an extensive survey of the lit-
erature [1], and since then the number of species has
increased substantially due to the increasing worldwide
interest in anti-malarial plants. In traditional practice,
several plants are often used in combination. Some of
them have been screened as crude extracts for in vitro
and/or in vivo anti-plasmodial activity directed to
the erythrocytic stage of malaria parasites. Single active
anti-plasmodial constituents have been successfully
characterized from some extracts, following the pharma-
ceutical industry paradigm of drug discovery [2-4].
In other cases, it has not been possible to isolate
active constituents from active extracts. Several explana-
tions have been proposed for this, such as the poor
quality of ethnopharmacological studies, plant material
processing, preclinical laboratory protocols which are
often very different from local practices, an inadequate
fractionation process, degradation of active constituents
during fractionation and poor biological models to
demonstrate activities. Nevertheless one hypothesis that
has not been extensively exploited in conventional anti-
malarial therapy is synergistic interaction or multi-fac-
torial effects between compounds present in herbal
extracts [5,6]. The principal synergistic combination
anti-malarials currently produced are Malarone
®
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Pure drugs that are industrially produced or isolated
from plants may be chosen for their high activity against
a human disease, but they have disadvantages. They
rarely have the same degree of activity as the unrefined
extract at comparable concentrations or dose of the
active component [10]. This phenomenon is attributed
to the absence of interacting substances present in the
extract. Furthermore, many plants contain substances
that inhibit multi-drug resistance (MDR). A further dis-
a d v a n t a g ei st h a tp u r ed r u g sa r eo f t e nm o r ee x p e n s i v e
to produce and distribute, and so are often unavailable
and/or unaffordable to the poorest populations in
remote areas who need them most. In contrast, herbal
medicines can sometimes be grown and produced
locally, at lower cost, by or close to those who need
them [11].
The aim of this paper is to review positive interactions
between components of whole plant extracts, which may
explain why crude extracts are often more effective than
isolated constituents at an equivalent dose. In some
cases this has been exploited in the making of combined
drugs. However, it is possible that a valid complemen-
tary approach is the use of standardized crude herbal
medicines and/or combinations for the treatment of
malaria, if their safety and efficacy are clinically
demonstrated.
The notion of synergy – evolutionary basis and
mechanisms
Plants survive in a hostile environment of predatory
micro- and macro-organisms in part by tough and dur-
able external structures and by rapid growth and repro-
duction, but their main defences are chemical. Defensive
chemicals may be present at all or certain periods of
growth, and in determined locations in the plant, they
may be generated after a predatory attack has been
inflicted or they may be exuded into the air or soil [12].
In contrast to animals, plants do not have an adaptive
immune system, so their chemical shield must cover
completely the entire spectrum of macro- and micro-
organisms that exist in their natural habitat and endan-
ger their existence. However it must be recognized that
groups of species growing in proximity often contribute
to a collective shield [12]. The chemical defence is lar-
gely made up of relatively small molecules that fit into
sites in enzymes or receptors of the predator interfering
with its life processes.
Over time, the attacking organisms often develop
resistance to the plant’s defences, and plants co-evolve
to produce resistance inhibitors [13], resulting in a great
complexity of phytochemicals in every species. Indeed if
plants followed the pharmaceutical model of producing
only a single compound against microorganisms which
threaten them, they would probably not survive for very
long. Metabolic processes in animal parasites are often
mediated by enzymes and receptor molecules that pos-
sess sites which will accommodate the plant chemical
defence substances, so it is not surprising that these
plant defences may also serve against agents of animal
diseases such as malaria.
In many cases there is evidence of synergy, but the
exact mechanisms have not been elucidated. Several
mechanisms may also be operating in parallel. For
example Artemisia annua (Asteraceae) is now one of
the best known anti-malarial plants [14]. The use of her-
bal teas prepared from the dried leaves of locally grown
A. annua is being promoted as an alternative treatment
for malaria in areas where people do not have access to,
or cannot afford effective anti-malarials such as artemi-
sinin combination therapy [11]. In a recent study,
extracts were obtained from fresh A. annua herb either
by soaking the herb in water followed by wringing out
the juice by hand or by pounding the fresh herb to a
pulp followed by squeezing out the juice [15]. The
extracts were then analysed for artemisinin concentra-
tion and tested against malaria parasites. It was found
that the anti-plasmodial IC50 values were 6 to 18-fold
lower than was expected in terms of their artemisinin
content suggesting that the activity of the extracts could
not be accounted for entirely by their artemisinin con-
tent. In mice infected with Plasmodium berghei,t h e
pounded juice (two doses of 500 μL, 12 h apart) equiva-
lent to 18 mg/kg artemisinin suppressed parasitaemia by
95% compared with artemisinin 30 mg/kg as a single
dose which suppressed parasitaemia by 88% [15]. In
mice infected with P. berghei given a crude ethanolic
extract of A. annua formulated with oil in a soft gel
capsule, the ED50 value with respect to the artemisinin
content was 35.1 mg/kg whereas the ED50 of pure arte-
misinin was 122 mg/kg [16]. These results suggest that
compounds in the juice and crude ethanolic extract
enhanced the action of artemisinin but whether this was
due to pharmacodynamic or pharmacokinetic effects (or
both) is impossible to say (although in the case of the
juice it could have been due to administering it in
divided doses). When the soft gel capsules were given to
malaria patients in doses equivalent to 217 mg artemisi-
nin over three days the treatment was effective in redu-
cing fever and clearing parasites but a high rate of
recrudescence was observed, although this was reduced
with a longer duration of treatment [16].
In pharmacodynamic synergy, a number of substances
act at different receptor targets involved in the disease
to enhance the overall therapeutic effect. Synergy
between different constituents of extracts has been
documented not only for anti-malarial activity, but also
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cokinetic synergy, substances with little or no activity on
the causative agent assist the main active principle to
reach the target by improving bioavailability, or by
decreasing metabolism and excretion. Other positive
interactions include complementary mechanisms of
action (such as immunomodulation), reversal of resis-
tance, and modulation of adverse effects. Each of these
will be discussed in turn.
Pharmacodynamic synergy
Strictly speaking, “synergy” or “potentiation” means that
the effect of the combination is greater than the sum of
the individual effects. One of the best examples of anti-
malarial synergy demonstrated both in vitro and in clini-
cal trials is that between atovaquone and proguanil. The
activity of the combination is up to eight times greater
than that of the individual compounds [7,19]. Such high
levels of synergy are uncommon.
One example in natural products is the synergy
between the Cinchona alkaloids. Almost 30 alkaloids
have now been described in Cinchona bark [20], several
of which are active against Plasmodium falciparumin
vitro, and some of which are not [21]. The four most
well-known alkaloids are quinine with its d-isomer qui-
nidine, and cinchonine with its l-isomer cinchonidine,
all of which have anti-plasmodial activity. They are
found in varying proportions in different barks [22].
Interestingly, quinine is not the most potent of the alka-
loids: quinidine, dihydroquinidine and cinchonine all
have consistently lower 50% inhibitory concentrations
(IC50) in vitro [21]. The combination of quinine with
quinidine and cinchonine is 2-10 times more effective in
vitro against quinine-resistant strains (Table 1), and the
mixture of alkaloids has a more consistent effect than
any of the alkaloids used singly [23]. This mixture has
been used clinically although no published research has
investigated whether synergy also occurs in human
patients.
Although it is recognized that the dose of artemisinin
contained in herbal preparations is small compared to
clinically recommended doses [24-26], it is widely believed
that other compounds present in A. annua, especially fla-
vonoids, may act synergistically to enhance the action of
artemisinin [27-29]. The flavone casticin enhances the
in vitro activity of artemisinin by 3-5 fold [28]. Some other
hydroxy- polymethoxy flavone constituents (artemetin,
chrysosplenetin, chrysosplenol-D, cirsilineol, eupatorin –
see Figure 1) also produce enhancement of 1.1-2.2 fold
but in further work, casticin was less active than in the
first study (enhancement 1.3-fold) [27]. These results are
perhaps unexpected given the well established antioxidant
and free radical scavenging activities of flavonoids [30] and
also that the mode of action of artemisinin depends on the
formation of free radicals as a result of the interaction of
haem iron in malaria infected red blood cells with the
endoperoxide moiety of artemisinin [31]. Theoretically, it
might be expected that free radicals arising from artemisi-
nin would be effectively scavenged by Artemisia flavonoids
thus preventing them from causing damage to the parasite.
Possible reasons why the above flavonoids do not antago-
nize artemisinin in vitro may include difficulty in accessing
the parasite food vacuole (in contrast to basic anti-
malarials, such as chloroquine which readily accumulate
into the acidic vacuole, the phenolic nature of flavonoids
may impede entry due to their acidic nature). Also, the
above flavonoids may be relatively weak antioxidants since
they do not have some of the structural requirements
associated with high antioxidant activity in flavonoids.
These include the presence of a catechol group in ring B
and a hydroxyl group in position 3 [30,32]. As shown in
Figure 1, artemetin, casticin, chrysosplenetin and cirsilneol
do not have either of the above features, although
eupatorin has a 3-hydroxy group and chrysosplenol D pos-
sesses a 3’,4 ’- catechol moiety.
In the Total Oxyradical Scavenging Capacity (TOSC)
assay artemetin was found to have weak activity (relative
T O S Cv a l u eo f0 . 2 8c o m p a r e dt ot h ev i t a m i nDa n a l o -
gue, Trolox) [33], while casticin was shown to have a
marked inhibitory effect on lipid peroxidation (IC50 =
0.049 mM compared to 0.703 mM for the positive
control ascorbic acid), but it was inactive in the 1,1-diphe-
nyl-2-picrylhydrazine (DPPH) radical scavenging assay
[34]. Further work to clarify the mechanisms by which
these flavonoids enhance the anti-plasmodial action of
artemisinin and to determine the effects of other A. annua
constituents, especially those with high antioxidant/radical
scavenging activities would be worthwhile.
In addition to at least 46 flavonoid constituents,
A. annua also contains other phenolic compounds
including coumarins and phenolic acids [35] and the con-
tribution of all of these in combination may be important
for anti-malarial efficacy. The total antioxidant capacity
Table 1 IC50 (ng/ml) of cinchona alkaloids in vitro against
two clones of P. falciparum (cultured in erythrocytes
suspended in RPMI medium supplemented with 10% AB
serum and [3H]hypoxanthine) [23]
Alkaloid UPASx1
clone
1
UPASx3
clone
2
Quinine 45 280
Quinidine 22 80
Cinchonine 27 130
Quinine + Quinidine + Cinchonine
(equal parts)
33 25
ΣFIC (<0.5 indicates significant synergy) 1.15 0.18
1 = quinine-sensitive.
2 = quinine-resistant.
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cal absorbance capacity, ORAC) has been reported to be
remarkably high (1,125 and 1,234 μM Trolox equiv/g)
and among the four highest values reported for medicinal
plants [35].
There are also reports of synergy between extracts of
different plants which are traditionally combined, but
the mechanisms of the synergy have not yet been clari-
fied. Curcumin (a polyphenolic compound from tur-
meric, i.e. Curcuma longa root) has direct anti-malarial
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Figure 1 Structures of some flavonoids that contribute to the antiplasmodial properties of Artemisia annua and/or Bidens pilosa.
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Page 4 of 12activity [36,37] and turmeric is reported as a component
of traditional remedies for malaria and fever in India
and Samoa [38,39]. In combination with artemisinin,
curcumin prevents recrudescence of malaria parasites
and death in animal models [40]. In combination with
Andrographis paniculata and Hedyotis corymbosa
extracts, curcumin displayed a clear synergistic effect
in vitro using the isobologram method (fig 2), and also
in vivo in rodent malaria models [41].
Synergy has also been demonstrated in vitro between
extracts of Mitragyna inermis, Nauclea latifolia, Guiera
senegalensis,a n dFeretia apodanthera, traditionally used
in Mali to treat malaria. Individually these have potent in
vitro anti-malarial effects, and two combinations showed
greater than two-fold synergy and absence of cytotoxicity,
namely the methanol extract of Feretia apodanthera +
ursolic acid (from Mitragyna inermis), and the crude
alkaloids of Mitragyna inermis + tetrahydroharman (alka-
loid constituent of Guiera senegalensis) [42].
Combinations of Kenyan anti-malarial plants have also
shown synergy, both in vitro and in vivo [43,44]. When
tested in mice, the survival time achieved by chloro-
quine could not be matched by any single plant extract,
but was matched by two combinations of plant extracts
(Figure 3). However some other combinations demon-
strated antagonistic effects and reduced survival time,
implying increased toxicity, which was not predicted
in vitro. The combinations were devised by the research-
ers and did not represent traditional formulae. These
findings demonstrate that combinations can be useful,
but equally can be harmful. It is important to research
combinations in traditional use, and not to assume that
all combinations are synergistic.
Positive pharmacokinetic interactions
Bioavailability and metabolism of medicinal substances
can be dramatically affected by other plant constituents.
There are many possible mechanisms, including an
increase in permeability of the Plasmodium membrane
to anti-malarial substances, inhibition of pump mechan-
isms for eliminating the drugs, modification of absorp-
tion, distribution, metabolism and excretion of active
constituents. Metabolism may be inhibited in phase I
(mediated by cytochromes which often oxidize foreign
substances) and phase II (mediated by enzymes that
derivatize the oxidized substance so that it is rendered
harmless and excreted) [5,17,45].
Curcumin alone has poor oral bioavailability due to
glucuronidation in the small intestine. Piperine from
black pepper (Piper nigrum seeds) enhances the bioa-
vailability of curcumin by 2000% in humans, due to an
inhibition of this glucuronidation and slowing the gas-
trointestinal transit [46]. Black pepper is used as a com-
ponent of herbal anti-malarial remedies in India
[39,47-49]. In the same way piperine improves the bioa-
vailability of epigallocatechin gallate (EGCG) which may
improve its activity as a multi-drug resistance inhibitor
in vivo [50] (see also below the section on MDR
inhibitors).
A l t e r e dm e t a b o l i s mi se x e mplified by cytochrome
P450-CYP3A4 which is involved in the metabolism of
digoxin, warfarin, statins, methadone, HIV protease inhi-
bitors, steroids, macrolides, cyclosporin, and many other
drugs [51]. This cytochrome is inhibited by grapefruit
juice (with its bergamottin and hydroxy dihydro berga-
mottin) [52], curcumin [53], garlic [54] and red wine,
which may cause large increases in plasma levels of the
drugs. Interestingly grapefruit juice (Citrus paradisi)i s
used to treat fever in Nicaragua [55] and garlic (Allium
sativum) is used as a component of anti-malarial reme-
dies in India [39,49].
Cytochrome P450-CYP2B6 is involved in the human
liver metabolism of artemisinin and CYP3A4 may also
contribute particularly in individuals with low CYP2B6
Figure 2 Isobolograms of the in vitro interaction of curcumin with methanol extracts of Andrographis paniculata (B) and Hedyotis corymbosa (C),
in a chloroquine-resistant strain of P. falciparum (MRC-pf-303) [41]. The straight diagonal line represents the null hypothesis if there were no
interaction.
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induce its own metabolism [57]. Some of the many phe-
nolic constituents of A. annua may also inhibit these
enzymes and so enhance the action of artemisinin
in vivo. An important problem with the use of artemisi-
nin as monotherapy in the treatment of malaria is the
high rate of recrudescence which appears to be related
to the short half-life of this drug [58]. Inhibition of
metabolism of artemisinin leading to an increased half-
life could theoretically result in a reduction of recrudes-
cence. In healthy volunteers grapefruit juice doubles the
oral bioavailability of artemether [59], although this
combination has never been tested in malaria. Curcumin
inhibits both CYP2B6 and CYP3A4 [53], which may
partly explain the fact that, in combination with artemi-
sinin, it completely prevents recrudescence of malaria
parasites and death in animal models [40].
The absorption of artemisinin may also be modified
by other constituents of A. annua. In a pharmacokinetic
study in healthy volunteers given a herbal tea prepared
from the dried leaves of A. annua, artemisinin was
absorbed rapidly and maximum plasma concentrations
were reached 30 minutes after ingestion whereas other
studies reported maximum levels more than two hours
after the administration of artemisinin capsules [60].
These data suggest that artemisinin is more rapidly
absorbed from the herbal tea than from pure artemisi-
nin capsules, although the dose of artemisinin was
much less than that in the capsules (95 mg and 500 mg
respectively); however, no difference was seen in the
bioavailability of the two preparations. The extraction of
artemisinin in herbal teas has been shown to be better
than would be expected taking into account its poor
aqueous solubility and this appears to be due to solubi-
lizing effects of other constituents, which may also
explain the faster absorption of artemisinin seen with
the herbal tea.
Complementary mechanisms of action
Investigations on anti-malarial plants concentrate mainly
on killing the parasites but rarely consider other mechan-
isms. Many anti-malarial herbal remedies may exert their
anti-infective effects not only by directly affecting the
pathogen. At least part of their effect may be indirect, by
stimulating natural and adaptive defense mechanisms of
the host. The immune system of the host plays a major
role in complete suppression or elimination of the patho-
gens [61]. Extracts or single compounds that can stimu-
late innate and/or adaptive immunity may be able to
contribute to prophylaxis and treatment not only for
malaria, but also for diverse viral, bacterial, parasitic and
fungal diseases [62,63]. Unfortunately, little work has
18
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Boscia salicifolia +
Sclerocarya birrea (60:40)
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PBS (placebo)
Survival time (days)
Figure 3 In vivo anti-malarial activity of single and combined plant extracts in mice infected with Plasmodium berghei, treated with aqueous
extracts orally, at 100mg/kg [43].
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laxis and treatment of malaria. Picroliv, a standardized
fraction isolated from the ethanol extract of the root and
the rhizome of Picrorhiza kurroa (Scrophulariaceae) has
been reported to activate the host immune system.
Co-administration of Picroliv was found to enhance effi-
cacy of chloroquine against experimental murine malaria
[64]. A traditional Chinese mixture known as Juzen-
taiho-to suppressed murine malaria by increasing the
production of antibodies and interferon gamma [65].
The pathology of cerebral malaria is generally consid-
ered to be primarily of immunological origin [66]. Sev-
eral compounds with known effects on the immune
system were tested in a murine model of cerebral
malaria [67]. Of the compounds tested, it was found
that only curcumin and the synthetic Rho kinase inhibi-
tor fasudil had significant effects on the progression of
the disease. Although neither drug caused a reduction
in parasitaemia, survival of the treated mice was signifi-
cantly increased, and the development of cerebral
malaria was either delayed or prevented. The authors
concluded that an immunomodulator efficient in pre-
venting cerebral malaria should be administered
together with anti-plasmodial drugs, rather than singly,
to prevent severe malaria disease [114]. However there
is clearly a great difference between murine and human
malaria, and immunomodulatory effects have not yet
been tested clinically.
Multidrug resistance inhibitors
Multidrug resistance is a phenomenon which usually
involves a protein molecule or “pump” that straddles the
cell membrane and which captures from the cytosol,
often by lipophilicity, a foreign substance such as the
anti-malarial agent. Powered by ATP, the pump then
undergoes a conformational change which throws the
entering substance out of the cell. “P-glycoproteins”are
one class of such pumps.
Some herbal anti-malarials such as A. annua have
been used for several thousand years, but resistance
does not seem to have appeared at a significant level. In
contrast, most isolated and synthetic anti-malarials have
suffered from the appearance of resistant strains of Plas-
modium. Resistance to isolated artemisinin in Plasmo-
dium yoelii was detected at a very early stage [68] and
the first signs of artemisinin resistance are appearing in
Plasmodium falciparum from patients in Cambodia [69].
It has been shown that a number of drugs such as ver-
apamil and antidepressants can inhibit export of chloro-
quine from P. falciparum [70-72]; they provide evidence
of mechanisms that might occur with natural anti-
malarials or in mixed natural-non natural combinations.
Two of the A. annua flavones, chrysosplenol-D and
chrysosplenetin, have been shown to inhibit MDR in a
quite distinct microorganism, multi-drug resistant Sta-
phylococcus aureus [73]. Structurally, these flavones
have as substituents 3 to 4 methoxyl groups, and 1 to 2
hydroxyls but other substitution patterns may confer
activity. Bidens pilosa also contains a flavone (quercetin-
3, 3’-dimethylether rhamnoglucoside, see figure 1) that
contributes to the anti-malarial activity of the plant,
otherwise largely ascribed to polyacetylenes [74,75].
Bidens pilosa extract reverses resistance to chloroquine
[76]. Epigallocatechin-3-gallate (EGCG), the most abun-
dant tannin in green tea, is reported to be an MDR inhi-
bitor [77] and has anti-malarial activity which is additive
when combined with artemisinin [78]. Curcumin inhi-
bits P-glycoprotein [79] and potentiates the activity of
several anticancer drugs [80]; in this context it has been
found to be safe in humans even at the high dose of 8g
per day [81].
Alkaloids are also involved in resistance reversal.
Cinchonine is a P-glycoprotein inhibitor and a very
potent MDR blocker and so to a lesser extent so is qui-
nine itself [82,83]. Cinchonine has favourable physico-
chemical properties for entry into the Plasmodium cell
[84], and it has low toxicity in mice and rats [82].
Cinchonine has been used to good effect in combination
with chemotherapy for patients with lymphoproliferative
syndromes [85] and reverses resistance to quinine in
vitro [23]. Since similar mechanisms are involved in
malaria drug resistance [72,86], cinchonine should be
tested as a multidrug inhibitor to use in the treatment
of malaria with any proven active drug, natural or syn-
thetic, whose activity has declined due to resistance.
Interestingly some traditional healers have started
using medicinal plants in combination with chloroquine
to enhance its effect. Investigation of some such plants
in Madagascar has shown that they reverse chloroquine
resistance in vitro and in mouse models [70]. These
include bisbenzylisoquinoline alkaloids of Strychnopsis
thouarsii and Spirospermum penduliflorum [87], alka-
loids of Hernandia voyronii [88], and strychnobrasiline
and malagashanine from Strychnos myrtoides [89]. Three
indole alkaloids, icajine, strychnobrasiline and isoreticu-
line from Strychnos icaja, S. myrtoides and S. variabilis,
which have no intrinsic anti-malarial activity, have been
shown to reverse chloroquine resistance in in vitro tests
with P. falciparum [90].
Very few MDR inhibitors have been tested clinically.
The concept was proven in the case of chlorphenira-
mine reversing chloroquine resistance, but because of
differing pharmacokinetics, it needed to be given for
seven days [91]. More recently it has been shown that
azithromycin and chloroquine act synergistically in the
treatment of chloroquine-resistant falciparum malaria
[92]. Azithromycin also acts synergistically with
arteether in the treatment of multidrug-resistant rodent
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toides (containing strychnobrasiline and malagashanine)
has been tested clinically in combination with chloro-
quine but was only given for three days, and this was
not enough to reverse clinical resistance to chloroquine
[94]. Because of the short half-life of these natural pro-
ducts, a longer duration of treatment (at least seven
days) is probably necessary to produce a clinical effect.
Compounds which inhibit multidrug resistance prob-
ably exist in many more plants than are currently recog-
nized. These compounds often have little or no direct
antimicrobial effect, so would be discarded in the con-
ventional process of screening and bioguided fractiona-
tion. However, when combined with compounds which
in isolation have only moderate antimicrobial activity,
they may reveal a much higher level of activity [13].
Although many plant extracts have been screened
in vitro for anti-malarial activity, few have been tested
for their ability to alter resistance mechanisms.
Modulation of adverse effects
One of the main reasons given for isolating active com-
pounds in the classical pharmaceutical development
process is the elimination of potentially toxic but inac-
tive compounds. Of course, it is important to assess the
toxicity of whole plant extracts, but in many cases the
whole extracts are not toxic. For example crude extracts
of A. annua and Argemone mexicana are very safe at
therapeutic doses.
The assumption that active compounds are non-toxic,
and that inactive compounds are toxic, is often incor-
rect. Since the active compounds show toxicity to the
microorganism they are probably more likely to be toxic
to other organisms. For example in the case of Cinchona
bark, quinine is as toxic as the other major alkaloids
[95]. In humans, the average fatal dose of quinine for an
adult is 8g, although deaths have been reported from as
little as 6g in an adult and 3g in a child, which is only
3.3x the treatment dose (600mg three times daily in an
adult). The fatal dose of quinidine may be as little as
250mg in cases of hypersensitivity, but is usually much
greater [96]. As each alkaloid has a slightly different
side-effect profile, and a combination permits a lower
dose of each, paradoxically the combination may be less
toxic than the equivalent effective dose of a single com-
pound. A standardized mixture of cinchona alkaloids
has been developed and marketed as “Quinimax”.I t
contains 71.4% quinine, with 18.6% quinidine and 5%
cinchonine and is as effective as quinine in the treat-
ment of malaria. Quinimax produces less cinchonism
than quinine alone [9] and less prolongation of the QTc
interval (on electrocardiography) than quinidine [8].
Another classic example is the development of febrifu-
gine from the traditional Chinese remedy Changshan
(containing Dichroa febrifuga). The pharmaceutical
development process led to the isolation of the highly
active anti-malarial compound febrifugine, which was
impossible to use in clinical practice because of its
intense emetic effect [97], and also its liver toxicity
[98,115]. The traditional formulation [97] included sev-
eral hepatoprotective plants such as Glycyrrhiza glabra
[99], Ziziphus jujube [100] and Zingiber officinale [101].
Evidence from laboratory studies suggests that these
plant extracts may have attenuated any hepatotoxicity
from febrifugine, although this remains to be tested
clinically. Zingiber officinale is also reputed as an anti-
emetic, and the traditional formulation was anecdotally
much better tolerated than febrifugine [97]. There is
good clinical evidence for the anti-emetic effect of gin-
ger especially in pregnant women [102], although it has
not specifically been tested for its anti-emetic effect in
the context of malaria. Nausea and vomiting are also
common symptoms of malaria, which may explain the
widespread use of ginger as one component of tradi-
tional remedies for malaria in Nicaragua [55], India
[39,103], Sri Lanka [104] and Zambia [105].
Discussion and conclusions
One definition of what counts as significant synergy is at
least a two-fold increase in activity (ΣFIC <0.5) [106]. In
the context of a herbal medicine, however, lower levels
of synergy are still useful as they contribute to the over-
all effect. Although in theory it would be easy with
high-throughput screening to test millions of combina-
tions for potential anti-malarial synergy in vitro,t h i s
would miss any mechanisms which were dependent on
metabolism (both pharmacodynamic synergy of metabo-
lites, and pharmacokinetic synergy). For example dried
Quassia amara l e a ft e ai sm u c hm o r ea c t i v ein vivo
than in vitro [107].
Several anti-malarial phytomedicines are government
approved and produced in standard dosages in different
countries [108]. Two of these are combinations of
plants, “Ayush-64” [109] and “Malarial-5” [110]. How-
ever these combinations were not designed on the basis
of any evidence of synergy [109,110]. Other phytomedi-
cines contain only a single plant which may contain sev-
eral ingredients acting in synergy.
Although A. annua infusion is currently promoted as
a single-plant remedy [14], it was not used alone in tra-
ditional Chinese medicine. Further work to elucidate the
mechanisms involved in the interactions discussed
above would be worthwhile and this may lead to the
development of combinations of artemisinin with other
natural molecules as anti-malarial agents, and of
A. annua with other herbs.
There are several indications that curcumin may be
a useful combination agent: it has some direct
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in vitro and in vivo and synergistic with some other
anti-malarial plants; it inhibits cytochrome P450
e n z y m e sa n ds om a yp r o l o n gt h ep l a s m ah a l f - l i f eo f
anti-malarial drugs; it inhibits multidrug resistance; and
in animal models it seems to have immunomodulatory
effects, preventing the development of cerebral malaria.
Furthermore it is well tolerated even in very high doses.
Turmeric and black pepper are both widely available
and easily cultivated, more often as food spices than as
medicines. Therefore, combinations including these
would be good candidates to take forward into clinical
trials. Ginger would also be a useful adjunct for its anti-
emetic effect.
Cinchonine (or its source, Cinchona bark) is also a
promising candidate for clinical trials, as it offers several
mechanisms of action. As well as direct anti-malarial
activity, cinchonine is a resistance reverser and probably
has fewer side-effects than quinine. Whole Cinchona
bark extracts were shown to be clinically safe and effec-
tive for the treatment of uncomplicated falciparum and
vivax malaria in extensive clinical trials in the 1930s
[111-113]. Although a combination of cinchonine with
quinine has been shown to be safe and effective in clini-
cal trials [8,9], it has never been assessed for the clinical
treatment of drug-resistant malaria.
More research is needed on all of these individually
and collectively [10]. There has been virtually no clinical
research on potentially useful pharmacokinetic synergy
or immunomodulation. Much more clinical research is
needed on pharmacodynamic synergy, resistance reversal
and attenuation of side-effects. This could include clini-
cal trials of combinations of pure compounds (such as
artemisinin + curcumin + piperine) and of combinations
of herbal remedies (such as Artemisia annua leaves +
Curcuma longa root + Piper nigum seeds). The former
may enhance the activity of existing pharmaceutical pre-
parations, and the latter may improve the effectiveness
of existing herbal remedies for use in remote areas
where modern drugs are unavailable.
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